The BMAL1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human osteosarcoma cell line 143B. These cells feature a targeted disruption of the BMAL1 (ARNTL) gene, a core component of the circadian clock, providing a powerful loss-of-function model for investigating circadian control and its impact on cancer biology. The polyclonal nature ensures a heterogeneous population with diverse editing outcomes, mirroring physiological variability.
The 143B cell line is a highly metastatic human osteosarcoma line widely used to study bone cancer metastasis and mesenchymal tumor biology. Originating from a bone tumor, 143B cells exhibit aggressive properties, making them a relevant model for dissecting the molecular mechanisms underlying osteosarcoma progression, invasion, and therapeutic resistance.
BMAL1 functions as a core circadian transcription factor, heterodimerizing with CLOCK to drive the rhythmic expression of clock-controlled genes. Through E-box elements, BMAL1?CCLOCK complexes promote transcription of downstream targets such as PER1, PER2, CRY1, CRY2, and DBP, while repression is mediated by REV-ERB??. BMAL1 activity is modulated by upstream regulators including ROR??, ROR??, CK1??, GSK3??, and mTOR signaling. Beyond the clock, BMAL1 directly or indirectly influences expression of cell cycle regulators (c-Myc, p21, p53), apoptotic factors (BAX), and metabolic enzymes, linking circadian rhythms to fundamental cellular processes.
Disruption of BMAL1 in 143B cells creates a unique model to study the intersection of circadian disruption and osteosarcoma pathophysiology. Loss of BMAL1 is expected to impair rhythmic expression of clock-controlled genes, leading to aberrant cell cycle progression, altered apoptotic responses, and metabolic reprogramming. This knockout model enables dissection of BMAL1-dependent signaling networks that control metastatic behavior, including pathways regulated by p53 and c-Myc, and provides a platform to evaluate chronotherapeutic strategies in a bone cancer context.
Researchers can employ the BMAL1 Knockout 143B Polyclonal Cells in a variety of functional assays. Western blotting, RT-qPCR, and RNA-seq can assess changes in clock protein and gene expression; circadian bioluminescence reporters can measure rhythmicity loss. Proliferation, migration, invasion, and apoptosis assays allow phenotypic characterization, while drug sensitivity and metabolic flux studies facilitate exploration of BMAL1??s role in chemotherapy response and cellular metabolism. ChIP-qPCR provides insight into BMAL1?Ctarget interactions. For further information, please contact Ascent Research.
